GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
139,200
-900 (-0.64%)
Last updated: Apr 29, 2026, 2:00 PM KST

GC Biopharma Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Cash & Equivalents
49,37222,56349,706105,366186,060
Upgrade
Short-Term Investments
-000-0-
Upgrade
Trading Asset Securities
1,4321,4325,8006,94016,875
Upgrade
Cash & Short-Term Investments
50,80423,99555,506112,306202,935
Upgrade
Cash Growth
111.73%-56.77%-50.58%-44.66%-20.57%
Upgrade
Accounts Receivable
402,689386,526436,957394,155413,817
Upgrade
Other Receivables
2,4089,63511,97613,7789,624
Upgrade
Receivables
405,274404,812450,933409,433423,987
Upgrade
Inventory
891,582746,582516,245442,408454,976
Upgrade
Prepaid Expenses
11,7249,6384,1474,1573,275
Upgrade
Other Current Assets
10,86216,80612,31612,1335,346
Upgrade
Total Current Assets
1,370,2471,201,8331,039,148980,4371,090,519
Upgrade
Property, Plant & Equipment
960,461915,826952,703930,822899,847
Upgrade
Long-Term Investments
197,926225,340206,646216,273110,962
Upgrade
Goodwill
118,069125,614142,475142,475142,475
Upgrade
Other Intangible Assets
125,01072,53586,16676,73557,240
Upgrade
Long-Term Deferred Tax Assets
65,28649,94135,18527,83919,832
Upgrade
Long-Term Deferred Charges
94,214109,236109,24092,35377,691
Upgrade
Other Long-Term Assets
39,26543,27268,97253,82463,299
Upgrade
Total Assets
2,971,0952,743,8762,643,3142,525,5372,462,145
Upgrade
Accounts Payable
177,260156,818143,816121,270119,541
Upgrade
Accrued Expenses
71,16854,14034,000102,06685,781
Upgrade
Short-Term Debt
352,164367,092315,447182,000104,836
Upgrade
Current Portion of Long-Term Debt
256,58410,829202,8135,416120,539
Upgrade
Current Portion of Leases
14,79914,30414,33511,5809,887
Upgrade
Current Income Taxes Payable
9,2517,8732,04117,15828,338
Upgrade
Current Unearned Revenue
5422,0251,6297,0847,730
Upgrade
Other Current Liabilities
264,035156,394154,83594,16576,231
Upgrade
Total Current Liabilities
1,145,803769,475868,917540,738552,883
Upgrade
Long-Term Debt
253,501339,50684,891278,797280,343
Upgrade
Long-Term Leases
105,09696,412106,53697,75190,969
Upgrade
Long-Term Unearned Revenue
5,1677,4007,50014,04916,296
Upgrade
Pension & Post-Retirement Benefits
37,67716,8051,3561,1711,497
Upgrade
Long-Term Deferred Tax Liabilities
3,4674,0632,2131,3581,869
Upgrade
Other Long-Term Liabilities
26,11129,20032,03825,03118,531
Upgrade
Total Liabilities
1,576,8221,262,8601,103,451958,895962,388
Upgrade
Common Stock
58,43358,43358,43358,43358,433
Upgrade
Additional Paid-In Capital
396,224396,220393,605393,531385,821
Upgrade
Retained Earnings
796,529815,336872,989903,467867,353
Upgrade
Treasury Stock
-35,702-35,702-35,702-35,702-35,702
Upgrade
Comprehensive Income & Other
1,99318,35810,9128,394-1,134
Upgrade
Total Common Equity
1,217,4771,252,6451,300,2361,328,1221,274,771
Upgrade
Minority Interest
176,796228,371239,627238,520224,987
Upgrade
Shareholders' Equity
1,394,2731,481,0161,539,8631,566,6421,499,757
Upgrade
Total Liabilities & Equity
2,971,0952,743,8762,643,3142,525,5372,462,145
Upgrade
Total Debt
982,144828,142724,022575,543606,574
Upgrade
Net Cash (Debt)
-931,340-804,147-668,516-463,238-403,639
Upgrade
Net Cash Per Share
-81602.53-70458.10-58574.02-40587.96-35366.01
Upgrade
Filing Date Shares Outstanding
11.4111.4111.4111.4111.41
Upgrade
Total Common Shares Outstanding
11.4111.4111.4111.4111.41
Upgrade
Working Capital
224,444432,358170,231439,698537,637
Upgrade
Book Value Per Share
106673.41109754.26113924.12116367.45111692.86
Upgrade
Tangible Book Value
974,3981,054,4961,071,5951,108,9121,075,056
Upgrade
Tangible Book Value Per Share
85375.2392392.8293891.0597160.6994194.24
Upgrade
Land
17,52417,50917,34617,38318,025
Upgrade
Buildings
714,516705,071695,794638,353572,756
Upgrade
Machinery
453,357430,546407,055369,503333,326
Upgrade
Construction In Progress
70,94743,02859,224103,334150,176
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.